Own Experience with the Non-standard Etanercept Dose Regimen and Its Advantages

Czech version

Authors: M. Tichý; D. Ditrichová
Authors‘ workplace: přednostka doc. MUDr. Dagmar Ditrichová, CSc. ; Klinika chorob kožních a pohlavních LF UP a FN Olomouc
Published in: Čes-slov Derm, 86, 2011, No. 6, p. 274-278
Category: Pharmacologyand Therapy, Clinical Trials

Overview

Assesment of optimal treatment doses of particular biologicals and establishment of standard dose regimens for psoriasis is based on the large randomized trials. In specific situations the different dose regimen can be indicated, usually, using short term higher doses to achieve quick remission. Lower than standard recommended doses are used less often, mainly due to apprehension of non-sufficent treatment effect. Experience with low etanercept dosing in the treatment of severe psoriasis and its advantages are described in this article.

Key words:
psoriasis – etanercept – dose regimens

Sources

1. BENÁKOVÁ, N., ŠTORK, J. Léčba psoriázy biologiky. Konsensuální doporučené postupy České dermatovenerologické společnosti ČLS JEP 2006. Čes Slov Derm, 2006, 81 (4) Suppl., S1-11.

2. DOHERTY, S. D., van VOORHEES, A., LEBWOHL, M. G., et al. National psoriasis foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J. Am. Acad. Dermatol., 2008, 59, p. 209–217.

3. DRIESSEN, R. J. B., van de KERKHOF, P. C. M., De JONG, E. M. G. J. Etanercept combined with methotrexate for high-need psoriasis. Br. J. Dermatol., 2008, 159, p. 460–463.

4. ELEWSKI, B., LEONARDI, C., GOTTLIEB, A. B., et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br. J. Dermatol., 2007, 156, p. 138–142.

5. GISONDI, P., DEL GIGLIO, M., COTENA, C., GIROLOMONI, G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, ivestigator-blinded pilot trial. Br. J. Dermatol., 2008, 158, p. 1345–1349.

6. GOMEZ-REINO, J. J., CARMONA, L., ANGEL, D. M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum., 2007, 57, p. 756–761.

7. GORDON, K. B., LANGLEY, R. G., LEONARDI, C. et al. Clinical Response to Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: Double-Blind, Randomized Controlled Trial and Open_Label Extension Study. J. Am. Acad. Dermatol., 2006, 55 (4), p. 598–606.

8. GRIFFITHS, C. E., CHRISTOPHERS, E., BARKER, J. N., et al. A classification of psoriasis vulgaris according to phenotype. Br. J. Dermatol., 2007, 156, p. 258–262.

9. CHRISTOPHERS, E. Comorbidities in psoriasis. J. Eur. Acad. Dermatol. Venereol., 2006, 20, p. 52–55.

10. LEONARDI, C. L., KIMBALL, A. B., PAPP, K. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet, 2008, 371, p. 1665-1674.

11. LEONARDI, C. L., POWERS, J. L., MATHESON, R. T., et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med., 2003, 349, p. 2014–2022.

12. MENTER, A., TYRING, S. K., GORDON, K. et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J. Am. Acad. Dermatol., 2008, 58, p. 106–115.

13. MOORE, A., GORDON, K. B., KANG, S. et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J. Am. Acad. Dermatol., 2007, 56, p. 598–603.

14. PALLER, A. S., SIEGFRIED, E. C, LANGLEY, R. G. et al. Etanercept treatment for children and adolescents with plaque psoriasis. N. Engl. J. Med., 2008, 358, p. 241–251.

15. PATHIRANA, D., ORMEROD, A. D., SAIAG, P. et al. European S3 0 Guidelines on systemic treatment of psoriasis vulgaris. J. Eur. Acad. Dermatol. Venereol., 2009, 23 (suppl. 2), p. 1–70.

16. REICH, K., NESTLE, F. O., PAPP, K. et al. Infliximab induction and maintenance therapy for moderate -to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet, 2005, 366, p. 1367–1374.

17. SMITH, CH., ANSTEY, A. V., BARKER, J. N. et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br. J. Dermatol., 2009, 161 (5), p. 987–1019.

18. ŠPERL, J., ŠPIČÁK, J. Problematika virových hepatitid v průběhu léčby preparáty s anti-TNF alfa aktivitou. Biologická léčba, 2009, 2, s. 69–75.

19. TICHÝ, M., DITRICHOVÁ, D. Biologika v léčbě těžkých forem psoriázy. Dermatol. praxi, 2007, 1, s. 19–21.

20. ICHÝ, M., DITRICHOVÁ, D. Biologická léčba v dermatologii. Klin. Farmakol. Farm., 2008, 22 (2), s. 68–71.

21. TYRING, S., GORDON, K. B., POULIN, Y. et al. Long- -term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch. Dermatol., 2007, 143, p. 719–726.

22. van de KERKHOF, P. C. M., SEGAERT, S., LAHFA. M. et al. One weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomised controlled trial with open-label extension. Br. J. Dermatol., 2008, 159, p. 1177–1185.

Labels

Dermatology & STDs Paediatric dermatology & STDs

Pigmented Naevi and Their Relationship to Malignant Melanoma

Erythema Elevatum Diutinum

Article was published in

Czech-Slovak Dermatology

2011 Issue 6